21 completed, 2 recruiting. 9 Phase 3, 7 Phase 2, 3 Phase 4, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 8, Recruiting 1 |
| Phase 2 | 7 | Completed 7 |
| Phase 4 | 3 | Completed 3 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow Meningococcal Infection: new trials by email Literature Review of Meningococcal Infection trials Research Report on Meningococcal Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA), Menhycia® (ACYW135 Meningococcal Conjugate Vaccine [CRM197]) (CanSino Biologics Inc., China) - Meningococcal Infection, Healthy Volunteers | Phase 3 | Recruiting | Sanofi | 4568 | 2026-08-22 | 2026-10-19 |
| Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China MenACYW conjugate vaccine, MenACYW135 polysaccharide vaccine, MenAC conjugate vaccine - Meningococcal Infection, Healthy Volunteers | Phase 3 | Completed | Sanofi | 1602 | 2025-09-26 | 2026-10-19 |
| Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in Vietnam Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine - Meningococcal Infection, Healthy Volunteers | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 447 | 2024-01-18 | 2025-09-17 |
| Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US) Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine - Meningococcal Infection | Recruiting | Sanofi Pasteur, a Sanofi Company | 50 | 2021-03-05 | 2025-12-01 | |
| A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years Bivalent rLP2086 Vaccine, Licensed pediatric hepatits A vaccine, Normal Saline - MENINGOCOCCAL INFECTION | Phase 2 | Completed | Pfizer | 400 | 2015-08-01 | 2020-10-26 |
| Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation Meningococcal Diphtheria Toxoid Vaccine - Meningitis, Meningococcal Infection | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 300 | 2013-06-25 | 2022-04-19 |
| Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose blood sampling, bivalent rLP2086 - Meningococcal Infection | Phase 3 | Completed | Pfizer | 698 | 2012-09-07 | 2020-03-27 |
| Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Meningococcal polysaccharide diphtheria toxoid conjugate, Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate - Meningitis, Meningococcal Infection | Phase 4 | Completed | Sanofi Pasteur, a Sanofi Company | 1394 | 2012-07-01 | 2015-12-15 |
| Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers Meningococcal vaccine GSK 134612, SynflorixTM, Infanrix-IPV/HiberixTM - Meningococcal Infection | Phase 3 | Completed | GlaxoSmithKline | 753 | 2012-01-27 | 2019-08-06 |
| Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra® - Meningitis, Meningococcal Infection | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 834 | 2011-09-01 | 2014-11-18 |
| Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate - Meningitis, Meningococcal Infection | Completed | Sanofi Pasteur, a Sanofi Company | 116 | 2011-06-01 | 2016-11-11 | |
| Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®, Meningococcal Group C Conjugate vaccine: MenC - Meningitis, Meningococcal Infection | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 123 | 2011-05-01 | 2016-08-19 |
| A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra®) - Meningococcal Infection, Meningitis | Phase 3 | Completed | Sanofi | 300 | 2010-06-01 | 2012-02-06 |
| A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined), M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live - Meningitis, Meningococcal Infection | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 580 | 2009-12-16 | 2022-03-28 |
| Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine - Meningitis, Meningococcal Infection | Phase 3 | Completed | Novartis | 7744 | 2008-12-01 | 2013-07-09 |
| Dose Comparison Study of Menactra® in US Children Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate - Meningitis, Meningococcal Infection | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 333 | 2008-06-01 | 2016-04-14 |
| Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers Meningococcal Polysaccharide Tetanus Protein Conjugate, Meningococcal polysaccharide group C conjugated - Meningitis, Meningococcal Infection | Phase 1 | Completed | Sanofi Pasteur, a Sanofi Company | 360 | 2008-04-01 | 2018-02-06 |
| Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients Reminder/recall notices for vaccines - Human Papilloma Virus (HPV), Tetanus-diphtheria-acellular Pertussis (Tdap) | Not applicable | Completed | University of Colorado, Denver | 4807 | 2007-10-01 | 2013-06-25 |
| Immunogenicity of the Booster Dose of Two MenC Vaccines conjugated polysaccharide menC vaccine - Meningococcal Infection | Phase 4 | Completed | Centro Superior de Investigación en Salud Publica | 389 | 2007-01-01 | 2013-10-11 |
| Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune® Polysaccharide Diphtheria Conjugate Vaccine - Meningitis, Meningococcal Infection | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 234 | 2006-01-01 | 2014-02-14 |
Showing 20 of 23. Sign in to see all of them.
Meningococcal Infections (23) · Meningitis (13) · Chickenpox (1) · Diphtheria (1) · Haemophilus Infections (1) · Meningitis, Bacterial (1) · Neoplasm Metastasis (1) · Tetanus (1) · Whooping Cough (1)
Bacterial Infections (23) · Bacterial Infections and Mycoses (23) · Gram-Negative Bacterial Infections (23) · Infections (23) · Neisseriaceae Infections (23) · Nervous System Diseases (13) · Neuroinflammatory Diseases (13) · Actinomycetales Infections (1) · Bordetella Infections (1) · Central Nervous System Bacterial Infections (1) · Central Nervous System Diseases (1) · Central Nervous System Infections (1) · Clostridium Infections (1) · Corynebacterium Infections (1) · DNA Virus Infections (1)
Meningococcal Vaccines (10) · Tetanus Toxoid (3) · Vaccines (3) · CRM197 (non-toxic variant of diphtheria toxin) (2) · Chickenpox Vaccine (2) · Pneumococcal Vaccines (2) · pentacel (2) · 13-valent pneumococcal vaccine (1) · Blood Specimen Collection (1) · Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate (1) · Hepatitis A Vaccines (1) · Hepatitis B Vaccines (1) · Heptavalent Pneumococcal Conjugate Vaccine (1) · Herpes Zoster Vaccine (1) · Poliovirus Vaccine, Inactivated (1)
Sanofi Pasteur, a Sanofi Company (13) · Sanofi (3) · Novartis (2) · Pfizer (2) · Centro Superior de Investigación en Salud Publica (1) · GlaxoSmithKline (1) · University of Colorado, Denver (1)
United States (11) · China (3) · Finland (2) · Germany (2) · India (2) · Australia (1) · Canada (1) · Costa Rica (1) · Czechia (1) · Denmark (1) · Guatemala (1) · Lebanon (1) · Mexico (1) · Panama (1) · Peru (1)
Allison Kempe, MD, MPH (1) · Javier Diez-Domingo, PhD (1)
PMID 19927040, PMID 20375851, PMID 22094636, PMID 22566415, PMID 25285126, PMID 27642132, PMID 29550195, PMID 29784470, PMID 30770221, PMID 35144847, PMID 36087588, PMID 42862517
2014 (1), U01IP000129 (1)